Shots:

• The P-III trials evaluate NONS vs saline control in 306 patients with COVID-19 at 20 clinical sites across India
• The results showed that NONS reduced the SARS-CoV-2 log viral load by ≥94% within 24hrs. & ≥99% in 48hrs. In the high-risk group, a greater proportion of patients achieved clinical & virological cure, the median time to negative PCR (4 days vs 8 days), was safe & well-tolerated
• Glenmark has received CDSCO’s approval for NONS to treat COVID-19 & is expected to be available in India under the brand name FabiSpray. NONS has a marketing authorization as a Class I Medical Device in the EU & also approved in Israel, Thailand, Indonesia & Bahrain under the name enovid or VirX

Ref: Businesswire | Image: Clinical Trial Arena